Clinical Trial Update: Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Caelyx (liposomal doxorubicin) given biweekly in heavily pretreated patients with relapsed ovarian cancer, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Caelyx (liposomal doxorubicin)

Snippet

Sponsor: North Eastern German Society of Gynaecological Oncology | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-12-16